Egypt's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $51 Mn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $99 Mn in 2030. One of the main reasons propelling the growth of this market is government initiatives, Aging population. The market is segmented by Drug class and By distribution channel. Some key players in this market are EIPICO, Pharco, Amoun, Memphis Pharmaceutical, Eva Pharma, Almirall, Astellas Pharma, American Hospital of Paris, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, and others.
The Egypt Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $51 Mn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $99 Mn in 2030. In both industrialized and developing nations, chronic obstructive pulmonary disease (COPD) is regarded as a major source of morbidity and mortality and is a frequent community issue. By 2020, COPD is anticipated to rank as the third-leading cause of death.
The prevalence of COPD (Chronic Obstructive Pulmonary Disease) in Egypt is relatively high, with estimates suggesting that the disease affects approximately 7.5% of the population. The prevalence of COPD is higher among men than women, and it increases with age. Several factors contribute to the high prevalence of COPD in Egypt, including smoking, air pollution, and occupational exposure. Smoking is the most significant risk factor for COPD in Egypt, with approximately 25% of the population being smokers. Air pollution, particularly indoor air pollution from the use of solid fuels for cooking and heating, is also a significant risk factor for COPD in Egypt. Exposure to occupational dust and chemicals is another contributing factor, particularly in industries such as mining, construction, and agriculture.
Market Growth Drivers
COPD is a significant health problem in Egypt, with a high prevalence rate. According to a study published in the International Journal of Chronic Obstructive Pulmonary Disease, the prevalence of COPD in Egypt was found to be 12.2% in adults aged 40 years and older. This high prevalence of COPD is expected to drive demand for therapeutics in the market. Egypt has a growing geriatric population, and aging is a major risk factor for COPD. According to the World Bank, the percentage of the population aged 65 years and older in Egypt was 5.1% in 2020 and is projected to reach 7.2% by 2030. This demographic trend is expected to drive demand for COPD therapeutics. Smoking is a major risk factor for COPD, and smoking rates in Egypt are among the highest in the world.
According to the World Health Organization, 23.5% of adults in Egypt were smokers in 2019. This high smoking rate is expected to drive demand for COPD therapeutics. The COPD therapeutics market in Egypt is witnessing advancements in drug and device development, which are expected to drive market growth. For instance, new inhalers and nebulizers are being developed that are more effective and user-friendly than traditional devices. The Egyptian government is taking initiatives to improve healthcare infrastructure and services, which is expected to increase access to COPD therapeutics. The government has implemented several programs to improve primary healthcare services, including the provision of free COPD medications to patients.
Market Restraints
There is a lack of awareness among the general population about the causes, symptoms, and treatment options for COPD. This results in a delay in diagnosis and treatment, which can lead to further complications and exacerbations of the disease. The cost of COPD medications and devices can be a significant barrier to access for many patients, particularly those from lower-income households. The cost of treatment may deter some patients from seeking treatment or following through with prescribed treatment plans. Some COPD medications and devices may not be widely available in all parts of Egypt, particularly in rural areas. This can limit access to effective treatments for some patients. The COPD therapeutics market in Egypt is highly competitive, with many international and domestic players vying for market share. This competition can lead to pricing pressures and reduced profit margins for some companies. Despite the government's efforts to improve healthcare infrastructure, there are still significant gaps in healthcare services in Egypt, particularly in rural areas. This can limit access to COPD treatment and diagnosis, particularly for patients living in remote areas.
Key Players
The healthcare policy and regulatory framework in Egypt is governed by the Ministry of Health and Population (MoHP). The MoHP is responsible for formulating and implementing healthcare policies, regulations, and guidelines for the country. The regulatory framework for the pharmaceutical industry is overseen by the Egyptian Drug Authority (EDA), which is responsible for approving and regulating drugs and medical devices. The EDA is also responsible for enforcing regulations related to the manufacturing, import, and distribution of pharmaceutical products in Egypt.
In terms of healthcare policy, the Egyptian government has taken several initiatives to improve healthcare services and access to medication for its citizens. The government has implemented several programs to improve primary healthcare services, including the provision of free medications for certain chronic diseases, including COPD. In addition, the Egyptian government has taken steps to improve the affordability of medication. The government has implemented price control measures for essential medications, which include several COPD medications. This has helped to make these medications more affordable for patients.
In Egypt, the government provides some form of reimbursement for certain medications and treatments for patients with COPD. The government has implemented several programs to improve access to essential medications, including those used to treat COPD. The government provides free medications for certain chronic diseases, including COPD. Under the national health insurance system, eligible patients can receive free medications and treatments for their condition. However, not all medications used to treat COPD are covered under this program.
Private health insurance companies also provide some form of reimbursement for COPD medications and treatments. However, the extent of coverage and reimbursement rates may vary depending on the specific insurance plan.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug Class
By Distribution Channel
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?